Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Press Release

Hyderabad, 12th August, 2024

NATCO records ₹1410.70 Crore consolidated revenue and ₹668.50 Crore of profit, after tax, for the First Quarter, FY2024-25

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of ₹1410.70 Crore for the first quarter ended on 30th June 2024, as against ₹1160.2 Crore for the same period last year, reflecting a growth of 21.6% in revenue. The net profit for the period, on a consolidated basis, was ₹668.50 Crores as against ₹420.3 Crore same period last year, showing 59% growth in profits.

The growth in revenue and profits were driven primarily by exports formulation business.

Segmental Revenue Split (All Figures in ₹ Crore)-

Segment	Revenue, Q1 FY25	Revenue, Q4 FY24	Revenue, Q1 FY24
API	39.2	50.0	75.1
Formulations, Domestic	102.2	52.4	132.4
Formulations, Exports (incl. Profit Share & Foreign Subs)	1210.10	954.9	884.2
Other Operating income & non-operating income	43.6	53.4	23.8
Crop Health Sciences (CHS)	15.6	(0.4)	44.7
TOTAL	**1410.7**	**1110.3**	**1160.2**

The Board of Directors has declared an interim dividend of ₹3.0 per equity share of ₹2.0 each, during Q1 of FY2025.

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer